Form 4: Adaptive Biotechnologies Director Sells Shares

Adaptive Biotechnologies Director Michelle Renee Griffin sold 15,394 shares of common stock for a weighted-average price of $13.91 per share.

Summary

• Michelle Renee Griffin, a Director at Adaptive Biotechnologies Corp (ADPT), executed a sale of common stock.
• The transaction involved 15,394 shares of common stock.
• The shares were sold on March 11, 2026, at a weighted-average price of $13.91 per share.
• The sale was conducted in multiple transactions ranging from $13.84 to $13.96, inclusive.
• Following the sale, Ms. Griffin directly beneficially owns 15,625 shares of common stock.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal, as a director's sale of a substantial number of shares, even if pre-planned, can suggest a lack of conviction or a belief that the stock is adequately priced.

Negatives

• A Director, Michelle Renee Griffin, sold a substantial number of shares (15,394) of Adaptive Biotechnologies common stock.
• The sale reduced her direct beneficial ownership to 15,625 shares, which could be interpreted as a lack of confidence or a belief that the stock is fully valued.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing, as it is an insider transaction report.

Industry Context

StockSavvy.ai notes that insider sales, especially by directors, are often scrutinized by investors as they can signal management's perception of future company performance or valuation. This specific transaction by a director at Adaptive Biotechnologies, even if pre-planned under a Rule 10b5-1 plan, could be interpreted as a belief that the stock is adequately valued or for personal financial planning reasons.

Stakeholder Impact

• Shareholders: May view the director's sale as a negative signal regarding future stock performance or valuation, potentially leading to increased scrutiny of the company's prospects.

Key Dates

Recommendation

The sale of a significant number of shares by a director, even under a Rule 10b5-1 plan, typically signals that the insider believes the stock is at least fairly valued, if not overvalued, or that they are reducing exposure for personal reasons. This action does not provide a positive catalyst for the stock and suggests a cautious approach for investors, warranting a 'hold' recommendation for existing positions rather than a 'buy'.

Keywords

Adaptive Biotechnologies, ADPT, insider trading, Form 4, stock sale, director, Michelle Renee Griffin, equity transaction, Rule 10b5-1